In cooperation with Boston Children’s Hospital, the center has recently been awarded an FDA grant to create a Pediatric Cardiovascular Device Consortium. Pediatric device development and evaluation has been recognized as a critical need to improve the lives and welfare of children with congenital and acquired illnesses. The numerous challenges faced by device developers and manufacturers have resulted in a large unmet need for pediatric devices and in particular, cardiovascular devices. The overall aim of the Pediatric Cardiovascular Device Consortium is to provide expertise and resources to device developers and manufacturers at each of the steps necessary for novel pediatric cardiac device development, in order to accelerate the pace of innovation.
The center has a challenge grant with Children’s Healthcare of Atlanta for Continuous Venovenous Hemofiltration (CVVH). Failure of the cardiac or respiratory system is a common problem in the pediatric and neonatal intensive care unit. When conventional management fails to improve the child's condition, extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) can serve to provide life-saving temporary heart and lung support. Studies have suggested that the addition of a renal replacement therapy such as continuous venovenous hemofiltration (CVVH) on ECMO can significantly improve fluid balance but use of this approach is hampered by potentially inaccurate fluid delivery/drainage by current intravenous fluid pumps, creating potential for excessive fluid removal and undesired degrees of dehydration. In an effort to promote aggressive fluid management and improve outcomes in critically ill children on ECMO by the use of CVVH, this project aims at developing a novel automated and accurate fluid management system. The new device employs a conservation of volume approach to limit the inaccuracies observed in typical IV pumps.
Dr. Yoganathan was recently appointed the founding editor in chief of Cardiovascular Engineering and Technology (CVET), a journal of the Biomedical Engineering Society. The journal will publish peer-reviewed articles ranging from basic to translational research in all aspects of cardiovascular physiology and medical treatment. CVET will serve as a forum for academic and industrial investigators to disseminate research that utilizes engineering principles and methods to advance fundamental knowledge and technological solutions related to the cardiovascular system. Biomedical Engineering Society: CVET
The 4th Biennial Heart Valve Biology and Tissue Engineering meeting will be held March 7 - 10 in Hilton Head Island, South Carolina. The meeting will focus on recent advances in valve biology and the development of tissue engineered heart valve replacements. The program has been designed to reflect the diversity of challenges faced by biologists, bioengineers, material scientists, clinicians and regulators and the multidisciplinary approach that is required for successful tissue engineering of heart valves. Heart Valve Biology and Tissue Engineering meeting
The center is involved in the development of International Standards for Minimally Invasive Heart Valve Technologies.
Dr. Yoganathan is featured in a television segment discussing cardiovascular surgical planning for children. Together with collaborators at Children’s Hospital of Philadelphia, Yoganathan and his research team in the Cardiovascular Fluid Mechanics Lab created a virtual tool to give surgeons a new way to predict and improve the outcome for pediatric heart patients. This innovative research was cited as an “engineering breakthrough” by IEEE-USA. Discoveries and Breakthroughs Inside Science is produced by Ivanhoe Productions and the American Institute of Physics and is distributed to 200 television stations around the world. For more information visit www.aip.org/dbis/IEEE/stories/20048.html